Fluorine in PDB 8bx9: Crystal Structure of JAK2 JH1 in Complex with Ilginatinib

All present enzymatic activity of Crystal Structure of JAK2 JH1 in Complex with Ilginatinib:
2.7.10.2;

The structure of Crystal Structure of JAK2 JH1 in Complex with Ilginatinib, PDB code: 8bx9 was solved by T.Haikarainen, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å)	67.14 / 1.40
Space group	I 1 2 1
Cell size a, b, c (Å), α, β, γ (°)	99.526, 68.883, 107.956, 90, 99.13, 90
R / Rfree (%)	19.1 / 22.3

The binding sites of Fluorine atom in the Crystal Structure of JAK2 JH1 in Complex with Ilginatinib (pdb code 8bx9). This binding sites where shown within 5.0 Angstroms radius around Fluorine atom.
In total 2 binding sites of Fluorine where determined in the Crystal Structure of JAK2 JH1 in Complex with Ilginatinib, PDB code: 8bx9:
Jump to Fluorine binding site number: 1; 2;

Fluorine binding site 1 out of 2 in the Crystal Structure of JAK2 JH1 in Complex with Ilginatinib


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 1 of Crystal Structure of JAK2 JH1 in Complex with Ilginatinib within 5.0Å range: probe atom residue distance (Å) B Occ A:F1201 b:15.9 occ:1.00 F09 A:S591201 0.0 15.9 1.0 C06 A:S591201 1.3 15.8 1.0 C07 A:S591201 2.4 13.7 1.0 C05 A:S591201 2.4 15.8 1.0 H071 A:S591201 2.6 16.4 1.0 HA A:ASN981 2.6 14.2 1.0 H051 A:S591201 2.6 19.0 1.0 HG A:LEU983 2.7 14.8 1.0 HA3 A:GLY993 2.7 14.5 1.0 C A:ASN981 3.0 11.0 1.0 H13 A:DMS1202 3.1 48.6 1.0 O A:ASN981 3.1 11.7 1.0 CA A:ASN981 3.3 11.9 1.0 HB2 A:ASP994 3.4 15.6 1.0 CA A:GLY993 3.4 12.1 1.0 N A:ILE982 3.5 11.8 1.0 C A:GLY993 3.5 12.3 1.0 C08 A:S591201 3.6 12.1 1.0 CG A:LEU983 3.6 12.3 1.0 H12 A:DMS1202 3.6 48.6 1.0 C04 A:S591201 3.6 14.9 1.0 O A:ARG980 3.7 12.1 1.0 H A:GLY993 3.7 12.2 1.0 N A:ASP994 3.8 13.0 1.0 C1 A:DMS1202 3.8 40.5 1.0 HD21 A:LEU983 3.9 13.8 1.0 C A:ILE982 3.9 13.0 1.0 H A:ASP994 3.9 15.6 1.0 O A:GLY993 3.9 12.1 1.0 H A:ILE982 3.9 14.2 1.0 HD11 A:LEU983 4.0 14.8 1.0 N A:GLY993 4.0 10.1 1.0 O A:ILE982 4.0 10.7 1.0 HA A:ILE982 4.0 15.1 1.0 CA A:ILE982 4.1 12.6 0.5 CA A:ILE982 4.1 12.0 0.5 HD23 A:LEU983 4.1 13.8 1.0 HB3 A:ASP994 4.1 15.6 1.0 CD2 A:LEU983 4.1 11.5 1.0 CB A:ASP994 4.1 13.0 1.0 C03 A:S591201 4.2 12.8 1.0 N A:ASN981 4.2 11.8 1.0 N A:LEU983 4.2 12.5 1.0 CD1 A:LEU983 4.2 12.3 1.0 HA2 A:GLY993 4.2 14.5 1.0 HB3 A:ASN981 4.3 15.7 1.0 HD12 A:LEU983 4.3 14.8 1.0 C A:ARG980 4.3 11.9 1.0 CB A:ASN981 4.4 13.1 1.0 H A:LEU983 4.4 15.0 1.0 H11 A:DMS1202 4.5 48.6 1.0 H081 A:S591201 4.5 14.5 1.0 CA A:ASP994 4.5 13.9 1.0 H041 A:S591201 4.5 17.8 1.0 HA A:LEU983 4.6 13.6 1.0 OD1 A:ASN981 4.6 16.6 1.0 CB A:LEU983 4.7 11.9 1.0 HA A:SER936 4.7 16.1 1.0 CA A:LEU983 4.7 11.3 1.0 H A:ASN981 4.9 14.1 1.0 HB2 A:LEU983 4.9 14.3 1.0 HB2 A:SER936 4.9 18.8 1.0 HA A:ASP994 5.0 16.7 1.0 HB3 A:SER936 5.0 18.8 1.0

Fluorine binding site 2 out of 2 in the Crystal Structure of JAK2 JH1 in Complex with Ilginatinib


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 2 of Crystal Structure of JAK2 JH1 in Complex with Ilginatinib within 5.0Å range: probe atom residue distance (Å) B Occ B:F1201 b:14.0 occ:1.00 F09 B:S591201 0.0 14.0 1.0 C06 B:S591201 1.3 13.9 1.0 C05 B:S591201 2.3 14.8 1.0 C07 B:S591201 2.4 11.3 1.0 H051 B:S591201 2.6 17.7 1.0 H071 B:S591201 2.6 13.6 1.0 HA B:ASN981 2.6 14.2 1.0 HG B:LEU983 2.7 14.1 1.0 HA3 B:GLY993 2.8 13.3 1.0 C B:ASN981 3.1 10.4 1.0 O B:ASN981 3.2 10.9 1.0 HB2 B:ASP994 3.3 16.5 1.0 CA B:ASN981 3.3 11.8 1.0 CA B:GLY993 3.5 11.1 1.0 C B:GLY993 3.5 10.0 1.0 C04 B:S591201 3.6 12.5 1.0 C08 B:S591201 3.6 13.0 1.0 N B:ILE982 3.6 10.8 1.0 CG B:LEU983 3.6 11.8 1.0 O B:ARG980 3.7 13.5 1.0 H B:GLY993 3.8 14.5 1.0 N B:ASP994 3.8 11.6 1.0 O B:GLY993 3.9 13.4 1.0 HD21 B:LEU983 3.9 15.2 1.0 H B:ASP994 3.9 13.9 1.0 HD11 B:LEU983 4.0 14.8 1.0 C B:ILE982 4.0 10.1 1.0 H B:ILE982 4.0 12.9 1.0 CB B:ASP994 4.0 13.8 1.0 HB3 B:ASP994 4.1 16.5 1.0 HD23 B:LEU983 4.1 15.2 1.0 N B:GLY993 4.1 12.1 1.0 CD2 B:LEU983 4.1 12.7 1.0 C03 B:S591201 4.1 12.9 1.0 O B:ILE982 4.2 11.9 1.0 CA B:ILE982 4.2 11.0 0.5 HA B:ILE982 4.2 13.2 1.0 CA B:ILE982 4.2 11.0 0.6 CD1 B:LEU983 4.2 12.4 1.0 N B:ASN981 4.2 12.4 1.0 O B:DMS1202 4.2 43.6 1.0 HD12 B:LEU983 4.3 14.8 1.0 HA2 B:GLY993 4.3 13.3 1.0 N B:LEU983 4.3 9.9 1.0 HB3 B:ASN981 4.3 14.3 1.0 C B:ARG980 4.4 11.4 1.0 CB B:ASN981 4.4 11.9 1.0 H041 B:S591201 4.5 15.1 1.0 CA B:ASP994 4.5 12.0 1.0 H081 B:S591201 4.5 15.6 1.0 H B:LEU983 4.5 11.9 1.0 OD1 B:ASN981 4.6 15.6 1.0 CB B:LEU983 4.7 10.6 1.0 HA B:LEU983 4.7 13.4 1.0 HA B:SER936 4.7 17.7 1.0 CA B:LEU983 4.8 11.2 1.0 HB2 B:LEU983 4.9 12.7 1.0 HA B:ASP994 4.9 14.3 1.0 H B:ASN981 5.0 14.9 1.0 HB2 B:SER936 5.0 19.4 1.0

Y.Miao, O.Silvennoinen, T.Haikarainen. Structural Basis For JAK2 Inhibition By Clinical Stage Inhibitors To Be Published.